SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
The mRNA strand carries genetic code. Cellular translation process. A ribosome synthesizes protein based on mRNA information. The ribosome decodes mRNA to form a protein chain. Molecular biology 3D illustration
Opinion
Opinion: Antagonism to mRNA Technology Is Killing Our Best Shot at a Cure for Cancer
The recent announcement of RFK Jr.’s termination of mRNA vaccine contracts is the latest effort to undermine this promising technology at the federal level. Pharmaceutical companies and private investors must fill the gap and ensure that research into this critical resource continues.
August 11, 2025
 · 
6 min read
 · 
Jonathan Kagan, PhD
GLP-1 injector pens and pills against colorful background
Obesity
5 Oral Obesity Drugs Challenging Lilly’s Orforglipron
Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.
August 11, 2025
 · 
10 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
FDA
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More
Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s Alzheimer’s drug Leqembi, which, according to Eisai, could “help reduce the burden on healthcare professionals and patients.”
August 11, 2025
 · 
5 min read
 · 
Tristan Manalac
FDA
Prasad Back at CBER After 10-Day California ‘Vacation’
After exiting the FDA less than two weeks ago for unclear reasons, Vinay Prasad is once again director of the Center for Biologics Evaluation and Research, HHS confirmed to several outlets Saturday.
August 9, 2025
 · 
2 min read
 · 
Heather McKenzie
medical laboratory equipment. robotic drug packaging.
Manufacturing
FDA Launches New PreCheck Program To Lower Regulatory Barriers to Pharma Manufacturing
Under PreCheck, the FDA will communicate more frequently with pharmaceutical companies, helping them as they establish or expand manufacturing sites in the U.S.
August 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.
Layoffs
Dewpoint Slashes Headcount by 70% as Cash Runway Runs Out
In December 2024, Dewpoint Therapeutics CEO Ameet Nathwani said the biotech’s cash runway would last until the third quarter of 2025.
August 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Earnings
Gilead Confident in PrEP Franchise Even Amid Preventive Task Force Uncertainties
The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV PrEP Yeztugo—that insurers must cover. A recently postponed meeting has raised concerns that Health Secretary RFK Jr. could abolish or overhaul the group.
August 8, 2025
 · 
2 min read
 · 
Tristan Manalac
A contemporary art collage depicting a giant ear listening to a message bubble while covering it with a hand. The concept of taking in a useful experience or overhearing a new idea.
Mergers & acquisitions
Novartis Continues Hunt for New Assets With Rumored Takeover of RNA Specialist Avidity
There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.
August 7, 2025
 · 
2 min read
 · 
Tristan Manalac
Man in low poly style before important choice stock illustration, decision, triple, three
Earnings
Lilly Faces Triple Threat of Drug Pricing Pressure as CEO Emphasizes Value
From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with Novo Nordisk, pricing was the number one issue for Eli Lilly on its second quarter earnings call.
August 7, 2025
 · 
3 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS